Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2024 - 2025)
Corvus Pharmaceuticals (CRVS) posted quarterly Gains from Investment Securities of -$2.0 million for Q2 2025, down 10.79% year-over-year from -$2.3 million in Q2 2024, and up 91.99% quarter-over-quarter from -$25.1 million in Q1 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Corvus Pharmaceuticals' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$2.0 million for Q2 2025.
- In Q2 2025, Gains from Investment Securities fell 10.79% year-over-year to -$2.0 million; the TTM figure through Dec 2025 stood at -$27.1 million (changed N/A YoY), while the FY2025 annual figure was -$27.1 million, down 181.26% from the prior year.
- Gains from Investment Securities for Q2 2025 stood at -$2.0 million, up from -$25.1 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $32.8 million in Q3 2024, with the low at -$25.1 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -25.13 Mn |
| Dec 31, 2024 | 2.37 Mn |
| Sep 30, 2024 | 32.85 Mn |
| Jun 30, 2024 | -1.82 Mn |